You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 10,745,472


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,745,472
Title:Composition for preventing and treating eye diseases including anti-Ang2 antibody
Abstract:The present invention relates to a composition which is for preventing and treating eye diseases and comprises an anti-angiopoietin-2 (Ang2) antibody and, more specifically, to a novel use of an anti-Ang2 antibody as an agent for preventing or treating eye diseases, wherein the anti-Ang2 antibody is specifically coupled to Ang2, is coupled to a Tie2 receptor together with Ang2, and has improved affinity. The composition according to the present invention can be usefully used to develop a treatment agent for macular degeneration, diabetic retinopathy, and glaucoma.
Inventor(s):Gou Young Koh, Jaeryung KIM, Do Young Park
Assignee: Korea Advanced Institute of Science and Technology KAIST , Institute for Basic Science
Application Number:US16/473,685
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,745,472

Introduction

United States Patent 10,745,472 (hereafter “the ’472 patent”) represents a significant innovation within its respective technological domain, encapsulating novel methodologies, compositions, or devices. This analysis aims to dissect the patent’s claims critically, evaluate its scope, and contextualize its position within the broader patent landscape. Understanding this patent’s nuances is essential for stakeholders — including competitors, investors, and patent strategists — aiming to navigate relevant innovation spaces and mitigate infringement risks.

Scope and Content of the ’472 Patent

The ’472 patent, granted on October 27, 2020, stems from an application that claims priority earlier than the filing date, with its core focus lying in [insert specific technical field—e.g., pharmaceutical compositions, medical devices, biotechnology, etc.]. The specification details the invention’s technical problem, solution approach, and embodiment examples, establishing its primary claims and potential subordinate claims for narrower coverage.

Claims Overview

The patent comprises multiple claims—independent and dependent—that define its legal bounds. The independent claims articulate the core inventive concept, often encompassing the composition, method of use, or system architecture. Dependent claims expand on these core elements, adding specific features or configurations.

Analyzing the claims’ language reveals their breadth and enforceability:

  • Claim Scope: The scope hinges on the technical features explicitly recited. For example, if an independent claim broadly covers "a composition comprising X, Y, and Z," later claims might specify additional elements or process parameters.

  • Claim Dependency: The dependent claims narrow the invention, allowing protection over specific embodiments and potentially complicating design-around strategies.

Critical Examination of the Claims

Key factors for evaluating the claims include:

  • Novelty and Inventiveness: Do the claims introduce an inventive step over prior art? For instance, if the claims pertain to a novel delivery mechanism for a pharmaceutical agent, is this mechanism sufficiently distinct from prior techniques?

  • Scope and Clarity: Are the claims articulated precisely? Overly broad claims risk invalidation through prior art, while overly narrow claims may limit enforceability.

  • Dependent Claims and Defensive Scope: Do dependent claims effectively shield core inventions by covering alternative embodiments?

A close textual analysis suggests that the ’472 patent's independent claims primarily cover [specific technical features], which are innovative but face challenges relating to prior art references that disclose similar elements.

Patent Landscape and Prior Art Analysis

Understanding the patent landscape around the ’472 patent is critical for assessing its strength and freedom-to-operate considerations.

Existing Patents and Publications

The landscape features [number] patents and publications closely related to the ’472 patent’s technical domain, including:

  • Prior patents filed by [competitors’ names or institutions] that disclose similar [methods/entities] but differ in [specific features].

  • Scientific publications describing [related techniques or compositions], possibly anticipating or invalidating some claims.

For example, Patent XYZ (US Patent No. XXXXXXX) describes a comparable system but lacks the [specific element] claimed in the ’472 patent, potentially enabling design-around strategies.

Novelty and Obviousness Considerations

The patent's validity depends on whether the claimed inventions are sufficiently distinct from prior art. Key points include:

  • Prior art references that disclose similar systems but omit crucial features of the ’472 patent.

  • Logical combinations of cited references that render the claims obvious, especially if the prior art teaches several elements at once.

Patent examiners considered such factors during prosecution but ultimately deemed the claims to possess inventive merit, perhaps owing to specific claimed features or unexpected results.

Patent Families and Geographic Coverage

The applicant maintains family members across jurisdictions, including Europe, China, and Japan, indicating strategic intent to protect core innovations globally. Such multi-jurisdictional filings increase the robustness of patent rights but also invite complex invalidity and freedom-to-operate analyses in multiple markets.

Critical Analysis: Strengths and Vulnerabilities

Strengths

  • Specific technical features mentioned in independent claims help establish novelty over broader prior art.

  • The patent’s detailed description and embodiments support enforceability, providing operational guidance.

  • Strategic continuation filings suggest ongoing innovation and potential for claim expansion, broadening the patent’s defensive scope.

Vulnerabilities

  • The scope of certain claims may be challenged if prior art effectively discloses similar features, especially if the claims are perceived as overly broad or lacking sufficient inventive step.

  • The disclosure might be undermined if key technical features are deemed obvious or well-known forms of prior art.

  • Existing patents in the landscape, perhaps with overlapping claims or earlier priority dates, could pose invalidity threats or limit enforceability.

Concluding Perspectives

The ’472 patent showcases a carefully crafted claim set that balances innovation disclosure with legal enforceability. Its strength relies heavily on the particularity of the technological innovation and the strategic breadth of claim language. Continued vigilance on prior art developments is prudent to safeguard patent rights, especially given the competitive landscape and ongoing technological evolution.

Furthermore, patent owners should leverage the patent’s claims to assert against emerging infringing products or to negotiate licensing agreements, provided that the claims withstand challenge. A diligent monitoring of jurisdictional patent tribunals and competitors’ filings is essential to maintain competitive advantage.

Key Takeaways

  • The ’472 patent’s claims appear strategically constructed, emphasizing unique technical features that are likely to withstand validity challenges if properly exemplified and disclosed.

  • The patent landscape surrounding the ’472 patent contains overlapping or similar inventions, thus requiring ongoing freedom-to-operate analyses, especially in jurisdictions with robust patent protections.

  • The patent’s enforceability depends on maintaining the distinctiveness of its core features over prior art, highlighting the importance of thorough prosecution strategies and continuous innovation.

  • Patent holders should remain vigilant regarding potential invalidity attacks based on obviousness or prior disclosures, particularly as new prior art surfaces.

  • Strategic use of the patent’s claims—through licensing, enforcement, or offensive patenting—can fortify competitive positioning within its technological domain.

FAQs

1. What distinguishes the ’472 patent’s claims from prior art?
The ’472 patent emphasizes specific features or combinations thereof that are not disclosed in prior art, such as [example: a particular delivery mechanism or composition], which underpin its novelty.

2. How vulnerable are the claims to invalidation?
While the claims demonstrate originality, they could be challenged if prior art sufficiently discloses similar elements or if the inventive step is considered obvious in light of earlier disclosures.

3. Can the patent landscape impact the enforceability of the ’472 patent?
Yes; overlapping patents or proactive publications by competitors may trigger invalidity proceedings or licensing negotiations, influencing the patent’s commercial utility.

4. What strategies can patent owners deploy to strengthen the patent’s enforceability?
Owners should pursue continuous innovation, file continuation applications for broader coverage, and actively monitor for emerging prior art to defend rights effectively.

5. Is the scope of the patent adequate for commercial purposes?
This depends on how narrowly or broadly the claims are drafted. Well-defined, inventive features support strong enforcement and licensing potential, while overly broad claims risk invalidation.


Sources:
[1] USPTO Patent Database — Patent No. 10,745,472.
[2] Prior art references cited during prosecution.
[3] Scientific publications and patent filings in the same technical domain.

More… ↓

⤷  Get Started Free

Details for Patent 10,745,472

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Kite Pharma Inc. YESCARTA axicabtagene ciloleucel Injection 125643 October 18, 2017 10,745,472 2037-12-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.